<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205162</url>
  </required_header>
  <id_info>
    <org_study_id>41693</org_study_id>
    <nct_id>NCT04205162</nct_id>
  </id_info>
  <brief_title>Evaluating the Initial Lens Handling Experience of Neophyte Contact Lens Wearers Fitted With Precision1 and 1-Day Acuvue Moist Contact Lenses</brief_title>
  <acronym>SALUKI</acronym>
  <official_title>Evaluating the Initial Lens Handling Experience of Neophyte Contact Lens Wearers Fitted With Precision1 and 1-Day Acuvue Moist Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Waterloo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The initial subjecting handling experience of neophyte contact lens wearers with Precision1&#xD;
      will be compared to that with a daily disposable lens which mas been on the market for&#xD;
      numerous years (1-Day ACUVUE Moist).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and Investigators will be masked to which lens type (brand) the participants will be wearing in each eye during the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective ratings of lens handling for insertion</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants rate the subjective handling of the lens for insertion on a scale from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective ratings of lens handling for removal</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants rate the subjective handling of the lens for removal on a scale from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Verofilcon A / Etafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etafilcon A / Verofilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verafilcon A</intervention_name>
    <description>Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)</description>
    <arm_group_label>Etafilcon A / Verofilcon A</arm_group_label>
    <arm_group_label>Verofilcon A / Etafilcon A</arm_group_label>
    <other_name>Precision1™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A</intervention_name>
    <description>Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)</description>
    <arm_group_label>Etafilcon A / Verofilcon A</arm_group_label>
    <arm_group_label>Verofilcon A / Etafilcon A</arm_group_label>
    <other_name>Acuvue® Moist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is between 18 and 40 years of age inclusively and has full legal capacity to&#xD;
             volunteer;&#xD;
&#xD;
          2. Has read and signed an information consent letter;&#xD;
&#xD;
          3. Is willing and able to follow instructions and maintain the appointment schedule;&#xD;
&#xD;
          4. Is a neophyte who has no history of any previous contact lens handling experience;&#xD;
&#xD;
          5. Has a refraction cyl ≤1.00DC in either eye (after vertexing to corneal plane);&#xD;
&#xD;
          6. Has visual acuity ≤0.20 logMAR each eye with study lenses;&#xD;
&#xD;
          7. Demonstrates acceptable fit with study lenses;&#xD;
&#xD;
          8. Demonstrates the ability to successfully insert and remove the study lenses 3 times&#xD;
             for each eye (contralateral CL handling, so that each lens type inserted and removed&#xD;
             3x on same eye);&#xD;
&#xD;
          9. Is willing to wear study CLs at least 5 days per week and 6 hours per day throughout&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is participating in any concurrent clinical or research study;&#xD;
&#xD;
          2. Has any known active* ocular disease and/or infection;&#xD;
&#xD;
          3. Has a systemic condition that in the opinion of the investigator may affect a study&#xD;
             outcome variable;&#xD;
&#xD;
          4. Is using any systemic or topical medications that in the opinion of the investigator&#xD;
             may affect a study outcome variable;&#xD;
&#xD;
          5. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;&#xD;
&#xD;
          6. Is pregnant, lactating or planning a pregnancy at the time of enrolment (by&#xD;
             self-report);&#xD;
&#xD;
          7. Is aphakic;&#xD;
&#xD;
          8. Has undergone refractive error surgery;&#xD;
&#xD;
          9. Has taken part in another clinical research study within the last 14 days;&#xD;
&#xD;
         10. Any ocular and/or systemic conditions or concomitant medication to contraindicate&#xD;
             contact lens wear or be expected to interfere with the primary outcome variables.&#xD;
&#xD;
               -  For the purposes of this study, active ocular disease is defined as infection or&#xD;
                  inflammation which requires therapeutic treatment. Mild (i.e. not considered&#xD;
                  clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction,&#xD;
                  papillae), corneal and conjunctival staining and dry eye are not considered&#xD;
                  active ocular disease. Neovascularization and corneal scars are the result of&#xD;
                  previous hypoxia, infection or inflammation and are therefore not active.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyndon Jones, PhD, FCOptom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Ocular Research &amp; Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Ocular Research &amp; Education</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

